These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2970142)

  • 1. Fine-needle aspiration cytology during treatment with orthoclone monoclonal antibody OKT3 for acute cellular rejection after renal transplantation.
    Hansen BL; Foged N; Nielsen E; Elbirk A; Rohr N; Svendsen V; Birkeland SA
    Transplant Proc; 1988 Aug; 20(4):626-8. PubMed ID: 2970142
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
    Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
    Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
    [No Abstract]   [Full Text] [Related]  

  • 5. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
    Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunohistological analysis of T lymphocyte subpopulations in needle core biopsies from OKT3-treated renal allograft recipients.
    Chauhan B; Mohanakumar T; Flye MW
    Transplantation; 1990 Dec; 50(6):1058-60. PubMed ID: 2147792
    [No Abstract]   [Full Text] [Related]  

  • 7. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
    Norman DJ
    Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
    Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
    Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse responses following intraoperative administration of orthoclone OKT3.
    Roth S; Kupferberg JP
    Anesth Analg; 1989 Dec; 69(6):822-5. PubMed ID: 2531559
    [No Abstract]   [Full Text] [Related]  

  • 11. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
    Ippoliti G; Fronterrè A
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
    [No Abstract]   [Full Text] [Related]  

  • 12. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
    Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
    [No Abstract]   [Full Text] [Related]  

  • 13. [Nephrotoxicity of anti-CD3 monoclonal antibodies].
    Alegre ML; Depierreux M; Florquin S; Abramowicz D; De Pauw L; Kinnaert P; Vereerstraeten P; Goldman M
    Nephrologie; 1991; 12(1):42-5. PubMed ID: 1827878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 15. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting.
    Burke GW; Vercellotti GM; Simmons RL; Howe RB; Canafax DM; Najarian JS
    Transplantation; 1989 Sep; 48(3):403-8. PubMed ID: 2528849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

  • 18. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
    Hirsch R; Bluestone JA; Bare CV; Gress RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
    [No Abstract]   [Full Text] [Related]  

  • 19. Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation.
    Toussaint C; De Pauw L; Vereerstraeten P; Kinnaert P; Abramowics D; Goldman M
    Transplantation; 1989 Sep; 48(3):524-6. PubMed ID: 2528851
    [No Abstract]   [Full Text] [Related]  

  • 20. Intrarenal inflammation during rejection crises in renal allografts: comparison between fine-needle aspiration cytology and renal biopsy.
    Mañalich R; Lagarde M; Cuellar C; Jimenez P
    Transplant Proc; 1988 Aug; 20(4):601-2. PubMed ID: 3043811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.